Eupraxia Pharmaceuticals Inc. (EPRX) vs EyePoint Pharmaceuticals, Inc. (EYPT)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and EyePoint Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.95HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
EYPT
EyePoint Pharmaceuticals, Inc.
$3.19HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — EPRX vs EYPT
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)EYPT -84.8% (-61.0%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX EYPT
EPRX vs EYPT: by the numbers
- •EYPT is the larger company ($267M vs $266M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | EPRX | EYPT |
|---|---|---|
| P/S ratio | N/A | 95.75 |
| P/B ratio | 2.62 | 1.60 |
Profitability
| Metric | EPRX | EYPT |
|---|---|---|
| Gross margin | 0.00% | 93.41% |
| Operating margin | 0.00% | -775.98% |
| Net margin | 0.00% | -10994.73% |
| ROE | -38.33% | -184.27% |
| ROIC | -43.56% | -170.19% |
Growth (annualized)
| Metric | EPRX | EYPT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -41.05% |
| Total return CAGR (5Y) | N/A | -21.68% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.